VITL, a Nashville-based e-prescribing platform for cash-pay clinics, has raised $7.5M in Series A funding led by SignalFire. The platform unifies access to vetted 503A/503B compounding pharmacies, enabling real-time price comparisons, multi-pharmacy ordering, and patient tracking. The capital will accelerate product development and team expansion to address infrastructure gaps in cash-pay health.
GLP-1 Surge Drives Pharmacy Demand
The funding arrives amid explosive demand for GLP-1 medications and compounded therapies in cash-pay practices like med spas and hormone clinics. Recent FDA warnings to 30 telehealth firms for illegal compounded GLP-1s highlight compliance risks, pushing clinics toward vetted pharmacy networks. VITL's focus on compliant, streamlined workflows positions it to capture this shift from fragmented legacy systems.
Legacy Portals Waste Clinic Time
Cash-pay health faces a $100 billion infrastructure problem, with clinics juggling multiple pharmacy portals. Physicians lose two full workdays per month on manual tasks like credentialing and price hunting, alongside $100,000 in annual productivity costs per clinic. Current tools built for insurance reimbursements fail to serve preventative care models prescribing peptides, HRT, and GLP-1s.
Unified Marketplace Replaces Portals
VITL's platform acts as a single login hub replacing seven separate portals, offering side-by-side price comparisons from vetted compounding pharmacies. Clinics order from multiple sources in one click with real-time patient tracking and unified billing. This eliminates "portalitis" and cuts prescription time dramatically.
As Charlie Jordan, founder and CEO, noted:
"We shorten the prescription time from several minutes down to a few seconds."
Unlike generalists like Surescripts optimized for insurance, VITL targets cash-pay efficiency.
SignalFire Validates Inbound Traction
SignalFire discovered VITL through its Beacon AI platform without a pitch, signaling strong data-backed momentum. The VC, with $3B AUM and healthtech portfolio including Ro and Grow Therapy, leads early-stage rounds in pharmatech infrastructure. This investment underscores VITL's eight-figure ARR and 90% QoQ growth in under two years since late 2024 founding.
E-Prescribing Market Scales Rapidly
The e-prescribing market stands at $7.61B in 2026, projected to reach $53.17B by 2034 at 26.84% CAGR, driven by digital adoption and specialty meds. Cash-pay and direct primary care growth, boosted by HSA eligibility for DPC starting 2026, amplifies demand. VITL serves 630+ clinics and 1,000+ prescribers amid shortages and regulatory shifts.
Telehealth Experts Lead Charge
Founder CEO Charlie Jordan brings 10+ years in digital health, including clinical ops at OpenLoop and VP telemedicine at OpenMed. Head of Operations Kyle Duke, former CIO at EvidenceCare and TennCare, led an acquisition and managed 1.4M-member Medicaid ops. Their combined expertise in telehealth and healthcare SaaS drives VITL's rapid scaling to 18 employees.
Hiring Fuels National Expansion
Post-funding, VITL ramps engineering and support hires, including backend engineers and customer support leads with pharmacy instincts. Implementation managers ensure smooth onboarding for growing clinic networks. With 90% QoQ order growth, the focus targets deeper penetration in med spas and longevity practices nationwide.